tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PTGX Stock Latest News

Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
25d ago
AEON
APRE
Protagonist Therapeutics price target raised to $70 from $58 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $70 from $58 at Wedbush
26d ago
PTGX
Protagonist Therapeutics price target raised to $76 from $60 at Truist
PremiumThe Fly
Protagonist Therapeutics price target raised to $76 from $60 at Truist
26d ago
PTGX
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital
PremiumThe Fly
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital
26d ago
PTGX
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright
PremiumThe Fly
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright
26d ago
PTGX
Protagonist reports top line results from Phase 2b study of icotrokinra
PremiumThe FlyProtagonist reports top line results from Phase 2b study of icotrokinra
27d ago
PTGX
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies
Premium
Ratings
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies
27d ago
PTGX
3 Best Stocks to Buy Now, 3/10/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 3/10/2025, According to Top Analysts
27d ago
ARCT
DOCU
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra
PremiumRatings
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra
27d ago
PTGX
Protagonist Therapeutics price target raised to $57 from $53 at JPMorgan
PremiumThe Fly
Protagonist Therapeutics price target raised to $57 from $53 at JPMorgan
1M ago
PTGX
Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating
PremiumRatings
Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating
1M ago
PTGX
Protagonist Therapeutics price target raised to $73 from $67 at BTIG
PremiumThe Fly
Protagonist Therapeutics price target raised to $73 from $67 at BTIG
1M ago
PTGX
Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating
PremiumRatingsProtagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating
1M ago
PTGX
Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential
Premium
Ratings
Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential
1M ago
PTGX
Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook
Premium
Ratings
Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook
1M ago
PTGX
Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships
PremiumRatings
Buy Rating for Protagonist Therapeutics: Strong Potential in Rusfertide and Strategic Partnerships
1M ago
PTGX
Protagonist Therapeutics: Buy Rating Backed by Promising Trials, Strategic Partnerships, and Strong Financial Position
PremiumRatings
Protagonist Therapeutics: Buy Rating Backed by Promising Trials, Strategic Partnerships, and Strong Financial Position
1M ago
PTGX
Protagonist Therapeutics Reports Strong 2024 Financial Results
PremiumCompany Announcements
Protagonist Therapeutics Reports Strong 2024 Financial Results
1M ago
PTGX
Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating
PremiumRatings
Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating
1M ago
PTGX
Protagonist Therapeutics price target raised to $54 from $50 at H.C. Wainwright
PremiumThe FlyProtagonist Therapeutics price target raised to $54 from $50 at H.C. Wainwright
1M ago
PTGX
Protagonist Therapeutics Faces Financial Risks Amidst Growing Pharmaceutical Pricing Pressures
Premium
Company Announcements
Protagonist Therapeutics Faces Financial Risks Amidst Growing Pharmaceutical Pricing Pressures
1M ago
PTGX
Protagonist Therapeutics Poised for Growth with Strong Data Prospects and Robust Financial Position
Premium
Ratings
Protagonist Therapeutics Poised for Growth with Strong Data Prospects and Robust Financial Position
1M ago
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >